Treatment of hypereosinophilic syndromes-the first 100 years

Seminars in Hematology

Volumn 49, Issue 2, 2012, Pages 182-191

  Butterfield, J H ^a   Weiler, C R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ALPHA2A INTERFERON; BENRALIZUMAB; CORTICOTROPIN; CORTISONE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DASATINIB; DEXAMETHASONE; DIURETIC AGENT; GLUCOCORTICOID; HYDROXYUREA; IMATINIB; INTERLEUKIN 5 ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; MEPOLIZUMAB; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MOMETASONE FUROATE; NILOTINIB; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; PREDNISOLONE; PREDNISONE; RESLIZUMAB; SORAFENIB; UNINDEXED DRUG;

ANGIONEUROTIC EDEMA; ANTICOAGULATION; APOPTOSIS; ARTICLE; ASTHMA; BRAIN DISEASE; CELL ACTIVATION; CELL EXPANSION; CELL INFILTRATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTAXIS; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PULSE THERAPY; ENZYME INHIBITION; EOSINOPHIL; EOSINOPHIL COUNT; EOSINOPHILIA; EOSINOPHILIC ESOPHAGITIS; EOSINOPHILIC GASTROENTERITIS; ERYTHEMA; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART FAILURE; HEART MUSCLE BIOPSY; HEART MUSCLE NECROSIS; HEART VALVE REPLACEMENT; HEPATOSPLENOMEGALY; HUMAN; HYPEREOSINOPHILIA; HYPEREOSINOPHILIC SYNDROME; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; LOADING DRUG DOSE; LOW DRUG DOSE; LYMPHOMA; MAINTENANCE DRUG DOSE; MONOTHERAPY; MULTIPLE ORGAN FAILURE; MYASTHENIA GRAVIS; MYOCARDITIS; NEUROLOGIC DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SKIN MANIFESTATION; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS REACTIVATION; VITAMIN BLOOD LEVEL;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTIVIRAL AGENTS; GLYCOPROTEINS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYDROXYUREA; HYPEREOSINOPHILIC SYNDROME; INTERFERON-ALPHA; INTERLEUKIN-5; PIPERAZINES; POLYETHYLENE GLYCOLS; PREDNISOLONE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECOMBINANT PROTEINS;

EID: 84858772703     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.01.001     Document Type: Article

References (91)

1. Hardy W.R., Anderson R.E. The hypereosinophilic syndromes. Ann Intern Med 1968, 68:1220.
2. Chusid M.J., Dale D.C., West B.C., et al. The hypereosinophilic syndrome: analysis of fourteen cases with a review of the literature. Medicine 1975, 1:54.
3. Parrillo J.E., Fauci A.S., Wolff S.M. Therapy of the hypereosinophilic syndrome. Ann Intern Med 1978, 89:167-172.
4. Prin L., Lefebvre P., Gruart V., et al. Heterogeneity of human eosinophil glucocorticoid receptor expression in hypereosinophilic patients: absence of detectable receptor correlates with resistance to corticotherapy. Clin Exp Immunol 1989, 78:383-389.
5. Peterson A.P., Altman L.C., Hill J.S., et al. Glucocorticoid receptors in normal human eosinophils: comparison with neutrophils. J Allergy Clin Immunol 1981, 68:212-217.
6. Lamas A.M., Leon O.G., Schleimer R.P. Glucocorticoids inhibit eosinophil responses to granulocyte-macrophage colony-stimulating factor. J Immunol 1991, 147:254-259.
7. Rolfe F.G., Hughes J.M., Armour C.L., et al. Inhibition of interleukin-5 gene expression by dexamethasone. Immunology 1992, 77:494-499.
8. Wallen N., Kita H., Weiler D., et al. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 1991, 147:3490-3495.
9. Meagher L.C., Cousin J.M., Seckl J.R., et al. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996, 156:4422-4428.
10. Kellgren J.H., Janus O. The eosinopenic response to cortisol and ACTH in normal subjects. Br Med J 1951, 2:1183-1187.
11. Parrillo J.E., Fauci A.S., Wolff S.M. The hypereosinophilic syndrome: dramatic response to therapeutic intervention. Trans Assoc Am Physicians 1977, 90:135-144.
12. Rothstein I., Spring M., Berley B.S. Effect of ACTH in a case of eosinophilic leukemia. NY State J Med 1953, 53:1461-1463.
13. Engfeldt B., Zetterstrom R. Disseminated eosinophilic collagen disease, a clinical and pathological study of a clinical entity related to Loffler's syndrome. Acta Med Scand 1956, 153:337-353.
14. Ogbogu P.U., Bochner B.S., Butterfield J.H., et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009, 124:1319-1325.
15. Bush R.K., Geller M., Busse W.W., et al. Response to corticosteroids in the hypereosinophilic syndrome. Association with increased serum IgE levels. Arch Intern Med 1978, 138:1244-1246.
16. Simon H.-U., Rothenberg M.E., Bochner B.S., et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010, 126:45-49.
17. Ito T., Harada K., Takada G. An infant with hypereosinophilic syndrome and heart failure markedly responded to prednisolone: serial changes of left ventricular wall thickening and left ventricular diastolic dysfunction observed by echocardiography. Heart Vessels 1998, 13:302-305.
18. Marshall G.M., White L. Effective therapy for a severe case of the idiopathic hypereosinophilic syndrome. Am J Pediatr Hematol Oncol 1989, 11:178-183.
19. Rizzari C., Cantu-Rajnoldi A., Masera G. Efficacy of prolonged low-dose steroid treatment in a child with idiopathic hypereosinophilic syndrome: a case report. Pediatr Hematol Oncol 1995, 12:209-212.
20. Venkatesh C., Mahender E., Janani S., et al. Hypereosinophilic syndrome. Indian J Pediatr 2006, 73:237-239.
21. Roufosse F., Weller P.F. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol 2010, 126:39-44.
22. Pitt M., Davies M.K., Brady A.J.B. Hypereosinophilic syndrome: endomyocardial fibrosis. Heart 1996, 76:377-378.
23. Yeung T., Lau S., Wong K. An unusual case of hypereosinophilic syndrome complicated with pulmonary thromboembolism and disseminated intravascular coagulation. Chin Med J 2005, 118:1582-1584.
24. Lee J.S., Lee H.-K., Lee S.S., et al. A case of idiopathic hypereosinophilic syndrome complicated with pulmonary thromboembolism and disseminated intravascular coagulation. Tuberculosis Respir Dis 2004, 57:573-578.
25. Davies J., Spry C.J.F., Sapsford R., et al. Cardiovascular features of 11 patients with eosinophilic endomyocardial disease. Q J Med 1983, 205:23-29.
26. Uetsuka Y., Kasahara S., Tanaka N., et al. Hemodynamic and scintigraphic improvement after steroid therapy in a case with acute eosinophilic heart disease. Heart Vessels 1990, 5(suppl):8-12.
27. Hayashi S., Isobe M., Okubo Y., et al. Improvement of eosinophilic heart disease after steroid therapy: successful demonstration by endomyocardial biopsied specimens. Heart Vessels 1999, 14:104-108.
28. Arsiwala S., Peek G., Davies M., et al. Hypereosinohilic syndrome: cause of prosthetic valve obstruction. J Thoracic Cardiovasc Surg 1995, 110:545-546.
29. Lebbink J., Laterre E.C. Idiopathic hypereosinophilic syndrome revealed by central nervous system dysfunction. Acta Neurol Belg 1996, 96:137-140.
30. Moreau Th, Derex L., Confavreux Ch Acute encephalopathy and idiopathic hypereosinophilic syndrome: clinical and MRI response to early steroid treatment. Eur J Neurol 1997, 4:618-621.
31. Ishida Y., Hayashi M., Higaki A., et al. Hypereosinohilic syndrome with generalized myasthenia gravis. J Pediatr 1996, 128:369-372.
32. Kazmierowski J.A., Chusid M.J., Parrillo J.E., et al. Dermatologic manifestations of the hypereosinophilic syndrome. Arch Dermatol 1978, 114:531-535.
33. Tsunemi Y., Idezuki T., Nakamura K., et al. Dermal endothelial cells express eotaxin in hypereosinophilic syndrome. J Am Acad Dermatol 2003, 49:918-921.
34. Offidani A., Bernardini M.I., Simonetti O., et al. Hypereosinophilic dermatosis: skin lesions as the only manifestation of the idiopathic hypereosinophilic syndrome?. Br J Dermatol 2000, 143:675-677.
35. Aragone M.D., Nigro A., Parodi A., et al. Solar urticaria as the presenting sign of hypereosinophilic syndrome. Int J Dermatol 1999, 38:234.
36. Valente A.I., Pinto H.C., Ramalho F., et al. Idiopathic hypereosinophilic syndrome presenting as cholestatic liver disease. Eur J Gastroenterol Hepatol 1997, 9:815-817.
37. Croffy B., Kopelman R., Kaplan M. Hypereosinophilic syndrome. Association with chronic active hepatitis. Dig Dis Sci 1988, 33:233-239.
38. Ichikawa N., Taniguchi A., Akama H., et al. Sclerosing cholangitis associated with hypereosinophilic syndrome. Intern Med 1997, 36:561-564.
39. Yarbro J.W. Mechanism of action of hydroxyurea. Semin Oncol 1992, 19:1-10.
40. Necas E., Hauser F. Analysis of the effect of hydroxyurea on stem cell (CFU-s) kinetics. Cell Tissue Kinet 1982, 15:39-47.
41. Robyn J., Lemery S., McCoy J.P., et al. Multilineage involvement of the fusion gene in patients with FIP1L1-PDGFRA-positive hypereosinophilic syndrome. Br J Haematol 2006, 132:286-292.
42. Demiroglu H., Dundar S. Combination of interferon-alpha and hydroxyurea in the treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 1997, 97:928-929.
43. Coutant G., Bletry O., Prin L., et al. Traitement des syndromes hypereosinophiliques a expression myeloproliferative par l'association hydroxyurea-interferon alpha. Ann Med Intern 1993, 144:243-250.
44. Diaz F., Collazos J. Reversible cerebellar involvement in the idiopathic hypereosinophilic syndrome. Postgrad Med J 1999, 75:477-479.
45. Murphy P.T., Fenelly D.F., Stuart M., et al. Alfa-interferon in a case of hypereosinophilic syndrome. Br J Haematol 1990, 75:619-620.
46. Zielinski R.M., Lawrence W.D. Interferon-α for the hypereosinophilic syndrome. Ann Intern Med 1990, 113:716-718.
47. Aldebert D., Lamkhioued B., Desaint C., et al. Eosinophils express a functional receptor for interferon α: inhibitory role of interferon α on the release of mediators. Blood 1996, 87:2354-2360.
48. Ochiai K., Iwamoto I., Takahashi H., et al. Effect of IL-4 and interferon-gamma (IFN-gamma) on IL-3 and IL-5-induced eosinophil differentiation from human cord blood mononuclear cells. Clin Exp Immunol 1995, 99:124-128.
49. Krishnaswamy G., Smith J.K., Srikanth S., et al. Lymphoblastoid interferon- α inhibits T cell proliferation and expression of eosinophil-activating cytokines. J Interferon Cytokine Res 1996, 16:819-827.
50. Butterfield J.H., Gleich G.J. Interferon- α treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 1994, 121:648-653.
51. Butterfield J.H. PEG-interferon after Interferon alfa-2b for hypereosinophilic syndrome. J Allergy Clin Immunol 2007, 119:S222.
52. Yamada O., Kitahara K., Imamura K., et al. Clinical and cytogenetic remission induced by interferon- α in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation. Am J Hematol 1998, 58:137-141.
53. Kouro T., Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol 2009, 21:1303-1309.
54. Gauvreau G.M., Ellis A.K., Denburg J.A. Haemopoietic processes in allergic disease: eosinophil/basophil development. Clin Exp Allergy 2009, 39:1297-1306.
55. Garrett J.K., Jameson S.C., Thomson B., et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 2004, 113:115-119.
56. Hart T.K., Cook R.M., Zia-Amirhosseini P., et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 2001, 108:250-257.
57. Sutton S.A., Assa'ad A.H., Rothenberg M.E. Anti-IL-5 and hypereosinophilic syndromes. Clin Immunol 2005, 115:51-60.
58. Rothenberg M.E., Klion A.D., Roufosse F.E., et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008, 358:1215-1228.
59. Smith D.A., Minthorn E.A., Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet 2011, 50:215-227.
60. Walsh G.M. Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions. Curr Opin Mol Ther 2009, 11:329-336.
61. Reichert J.M. Antibody-based therapeutics to watch in 2011. MAbs 2011, 3:76-99.
62. Kim Y.J., Prussin C., Martin B., et al. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol 2004, 114:1449-1455.
63. Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta Haematol 2005, 114:52-60.
64. Sefcick A., Sowter D., DasGupta E., et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol 2004, 124:558-559.
65. Pitini V., Teti D., Arrigo C., et al. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol 2004, 127:477.
66. Antoniu S.A. Novel therapies for hypereosinophilic syndromes. Neth J Med 2010, 68:304-310.
67. Wagner L.A., Speckart S., Cutter B., et al. Treatment of FIP1L1/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody. J Allergy Clin Immunol 2009, 123:1407-1408.
68. Verstovsek S., Tefferi A., Kantarjian H., et al. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res 2009, 15:368-373.
69. Perini G.F., Santos F.P., Hamerschlak N. Alemtuzumab in the reversal of encephalopathy associated with hypereosinophilic syndrome. Br J Haematol 2009, 147:592.
70. Elsner J., Hochstetter R., Spiekermann K., et al. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 1996, 88:4684-4693.
71. Busse W.W., Katial R., Gossage D., et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010, 125:1237-1244.
72. Kolbeck R., Kozhich A., Koike M., et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010, 125:1344-1353.
73. Pardanani A., Brockman S.R., Paternoster S.F., et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004, 104:3038-3045.
74. Gotlib J. Eosinophilic myeloid disorders: new classification and novel therapeutic strategies. Curr Opin Hematol 2010, 17:117-124.
75. Helbig G., Kyrcz-Krzemien S. Diagnostic and therapeutic management in patients with hypereosinophilic syndromes. Pol Arch Med Wewn 2011, 121:44-52.
76. Ikezoe T., Togitani K., Tasaka T., et al. Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib. Leuk Res 2010, 34:e200-e201.
77. Tabouret E., Charbonnier A., Mozziconacci M.J., et al. Low-dose Nilotinib can maintain complete molecular remissions in FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Leuk Res 2011, 35:136.
78. Lierman E., Michaux L., Beullens E., et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009, 23:845-851.
79. Lierman E., Folens C., Stover E.H., et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006, 108:1374-1376.
80. Baumgartner C., Gleixner K.V., Peter B., et al. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Exp Hematol 2008, 36:1244-1253.
81. Kioke T., Nakamura Y., Enokihara H. Interferon-á inhibits interleukin-5 and granulocyte-macrophage colony stimulating factor production by lymphocytes and suppresses eosinophil colony formation from bone marrow progenitor cells. Dokkyo J Med Sci 1998, 25:45-52.
82. Paul W.E., Seder R.A. Lymphocyte responses and cytokines. Cell 1994, 76:241-251.
83. Gutterman J.U. Cytokine therapeutics. lessons from interferon-á. Proc Natl Acad Sci USA 1994, 91:1198-1205.
84. Parronchi P., DeCarli M., Manetti R., et al. IL-4 and IFN (á andã) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J Immunol 1992, 149:2977-2983.
85. Krishnaswamy G., Smith J.K., Srikanth S. Lymphoblastoid interferon-á inhibits T cell proliferation and expression of eosinophil-activating cytokines. J Interferon Cytokine Res 1996, 16:819-827.
86. Enokihara H., Nakamura Y., Nagashima S., et al. Regulation of interleukin-5 production by interleukin-4, interferon-alpha, transforming growth factor â and interleukin-6. Int Arch Allergy Immunol 1994, 104:44-55.
87. Krishnaswamy G., Hall K., Youngberg G., et al. Regulation of eosinophil-active cytokine production from human cord blood-derived mast cells. J Interferon Cytokine Res 2002, 22:379-388.
88. Schoffski P., Ganser A., Pascheberg U., et al. Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(3;7) aberration. Ann Hematol 2000, 79:95-98.
89. Luciano L., Catalano L., Sarrantonio C., et al. áIFN-induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1;5). Haematologica 1999, 84:651-653.
90. Quiquandon I., Claisse J.F., Capiod J.C., et al. á-Interferon and hypereosinophilic syndrome with trisomy 8: karyotypic remission. Blood 1995, 85:2284-2285.
91. Ceretelli S., Capochiani E., Petrini M. Interferon-á in the idiopathic hypereosinophilic syndrome: consideration of five cases. Ann Hematol 1998, 77:161-164.